WO2004069167A3 - Methode et compositions pour le traitement de l'infertilite masculine - Google Patents
Methode et compositions pour le traitement de l'infertilite masculine Download PDFInfo
- Publication number
- WO2004069167A3 WO2004069167A3 PCT/US2004/002400 US2004002400W WO2004069167A3 WO 2004069167 A3 WO2004069167 A3 WO 2004069167A3 US 2004002400 W US2004002400 W US 2004002400W WO 2004069167 A3 WO2004069167 A3 WO 2004069167A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ejaculatory
- ovum
- apomorphine
- fertilization
- examples
- Prior art date
Links
- 208000007466 Male Infertility Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000002322 Egg Proteins Human genes 0.000 abstract 3
- 108010000912 Egg Proteins Proteins 0.000 abstract 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000004720 fertilization Effects 0.000 abstract 3
- 210000004681 ovum Anatomy 0.000 abstract 3
- 229960004046 apomorphine Drugs 0.000 abstract 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 abstract 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 abstract 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 1
- 229960003116 amyl nitrite Drugs 0.000 abstract 1
- 229960002802 bromocriptine Drugs 0.000 abstract 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 abstract 1
- 229960004596 cabergoline Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 abstract 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000009027 insemination Effects 0.000 abstract 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 abstract 1
- 229960000201 isosorbide dinitrate Drugs 0.000 abstract 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 abstract 1
- 229960003827 isosorbide mononitrate Drugs 0.000 abstract 1
- 229960003587 lisuride Drugs 0.000 abstract 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 abstract 1
- 208000008634 oligospermia Diseases 0.000 abstract 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 1
- 229960003089 pramipexole Drugs 0.000 abstract 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 abstract 1
- 229960001879 ropinirole Drugs 0.000 abstract 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 abstract 1
- 229950000366 roxindole Drugs 0.000 abstract 1
- BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960002381 vardenafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'utilisation d'agents permettant d'améliorer l'éjaculation permet de traiter des hommes présentant des spermatogrammes présentant un faible décompte de spermatozoïdes pour favoriser la fertilisation d'un ovule. Des agents d'amélioration de l'éjaculation sont utilisés pour favoriser des éjaculations plus fréquentes, ce qui permet de produire plus de sperme, et ainsi d'accroître la probabilité de fertilisation de l'ovule, puisque plus de sperme est disponible. La fertilisation de l'ovule peut s'effectuer par un rapport sexuel avec une femme, ou par fertilisation in vitro ou par insémination artificielle. Des exemples d'agents d'amélioration de l'éjaculation sont des agonistes du récepteur de la dopamine, des inhibiteurs spécifiques de la phosphodiestérase-5 (PDE-V), des nitrates organiques, de l'arginine L et des combinaisons de ceux-ci. Les agonistes du récepteur de la dopamine comprennent de l'apomorphine, un sel d'ajout pharmaceutiquement acceptable de l'apomorphine, et un dérivé de l'apomorphine, de la bromocriptine, du ropinirole, de la cabergoline, du pramipexole, du roxindole et du lisuride. Des exemples d'inhibiteurs de PDE-V comprennent le sildenafil, le tadalafil et le vardenafil. Des exemples de nitrates organiques comprennent du trinitrate de glycérol, du nitrure d'amyle, du dinitrate d'isosorbide, de l'isosorbide-5-mononitrate et du tétranitrate d'érythrityle.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44403203P | 2003-01-31 | 2003-01-31 | |
| US60/444,032 | 2003-01-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004069167A2 WO2004069167A2 (fr) | 2004-08-19 |
| WO2004069167A3 true WO2004069167A3 (fr) | 2004-10-28 |
Family
ID=32850819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/002400 WO2004069167A2 (fr) | 2003-01-31 | 2004-01-27 | Methode et compositions pour le traitement de l'infertilite masculine |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2004069167A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004038328A1 (de) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
| JP2009502961A (ja) | 2005-07-29 | 2009-01-29 | コンサート ファーマシューティカルズ インコーポレイテッド | 新規な医薬組成物 |
| MX2009008491A (es) * | 2007-02-12 | 2010-01-20 | Dmi Biosciences Inc | Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6338862B1 (en) * | 2001-03-26 | 2002-01-15 | Sarfaraz K Niazi | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors |
| US6506765B2 (en) * | 2000-04-07 | 2003-01-14 | Tap Pharmaceutical Products, Inc. | Apomorphine derivatives and methods for their use |
-
2004
- 2004-01-27 WO PCT/US2004/002400 patent/WO2004069167A2/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506765B2 (en) * | 2000-04-07 | 2003-01-14 | Tap Pharmaceutical Products, Inc. | Apomorphine derivatives and methods for their use |
| US6338862B1 (en) * | 2001-03-26 | 2002-01-15 | Sarfaraz K Niazi | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004069167A2 (fr) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0109577A (pt) | Composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para tratar cânceres em um animal de sangue quente | |
| WO2007146124A3 (fr) | Inhibiteurs de pde5 substitué | |
| MY128479A (en) | (beta)-carboline derivatives useful as inhibitors of phosphodiesterase | |
| CA2677691A1 (fr) | Reduction des effets secondaires du tramadol | |
| WO2001041807A3 (fr) | Administration a travers les muqueuses d'inhibiteurs de la phosphodiesterase dans le traitement de la dyserection | |
| WO2005051300A3 (fr) | Inhibiteurs bicycliques de mek et leurs procedes de production | |
| PE20010924A1 (es) | Compuestos inhibidores de fosfodiesterasa utiles para el tratamiento de la disfuncion sexual femenina | |
| WO2006104762A3 (fr) | Traitement d'humains de sexe masculin par supplementation en testosterone associee a un inhibiteur de 5alpha-reductase | |
| CA2360668A1 (fr) | Utilisation de derives du 4-h-1-benzopyran-4-one comme inhibiteurs de la proliferation des cellules de muscles lisses | |
| MY140872A (en) | 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders | |
| EP1505068A4 (fr) | DERIVE DE PYRAZOLO(1,5-a)PYRIMIDINE ET INHIBITEUR DE LA NAD(P)H OXYDASE CONTENANT LEDIT DERIVE | |
| GT200000168A (es) | Compuestos farmaceuticamente activos. | |
| WO2005034845A3 (fr) | Compositions et methodes de traitement du cancer | |
| NZ595393A (en) | Methods and compositions for improving pregnancy outcome | |
| RU2011133242A (ru) | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции | |
| WO2009151997A8 (fr) | Procédé de production de dérivés de bicycloaniline | |
| WO2007150025A3 (fr) | Dérivés de purinone en tant qu'agonistes du hm74a | |
| RU2009120990A (ru) | Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| MA31594B1 (fr) | Composes organiques | |
| Maw et al. | Design, synthesis and biological activity of β-carboline-based type-5 phosphodiesterase inhibitors | |
| TW200716607A (en) | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | |
| WO2006000577A3 (fr) | Procedes et compositions permettant de favoriser l'homeostasie osseuse | |
| CL2021003530A1 (es) | Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020. | |
| WO2004069167A3 (fr) | Methode et compositions pour le traitement de l'infertilite masculine | |
| CA2677690A1 (fr) | Traitement destine a une ejaculation precoce et aux troubles de l'erection comorbides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |